Abstracts tagged "osteoporosis"

Abstract Number: 916 • 2014 ACR/ARHP Annual Meeting
Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density
MR McClung¹, A Chines², JP Brown³, A Diez-Perez⁴, H Resch⁵, J Caminis⁶, MA Bolognese⁷, S Goemaere⁸, HG Bone⁹, JR Zanchetta¹⁰, J Maddox², O Rosen², S Bray¹¹ and A Grauer², ¹Oregon Osteoporosis Center, Portland, OR, ²Amgen Inc., Thousand Oaks, CA, ³Laval University and CHU de Québec Research Centre, Quebec City, QC, Canada, ⁴Autonomous University of Spain, Barcelona, Spain, ⁵St. Vincent Hospital, Vienna, Austria, ⁶UCB, Raleigh, NC, ⁷Bethesda Health Research Center, Bethesda, MD, ⁸Ghent University Hospital, Ghent, Belgium, ⁹Michigan Bone and Mineral Clinic, Detroit, MI, ¹⁰Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹¹Amgen Ltd., Cambridge, United Kingdom
Background/Purpose: We previously reported that 1 year of treatment with the sclerostin antibody romosozumab (Romo) was associated with increased bone mineral density (BMD) and bone…
Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…
Abstract Number: 111 • 2014 ACR/ARHP Annual Meeting
Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy
Mamatha Siricilla¹, Ruili Luo², Linda Elting² and Maria E. Suarez-Almazor¹, ¹The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Aromatase inhibitors (AI) are increasingly used as adjuvant hormonal therapy in postmenopausal women with estrogen receptor-positive breast cancer. It is well recognized that therapy…
Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Hiroto Yoshida¹, Mika Yagoto¹, Miho Suzuki¹, Keisuke Tanaka¹, Isao Matsumoto², Takayuki Sumida³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…
Abstract Number: 1924 • 2013 ACR/ARHP Annual Meeting
Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data
Chad L. Deal¹, Gregory J. Strnad², Robert A. Overman^3,4 and Boris Bershadsky^2,5, ¹Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH, ²Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH, ⁵School of Public Health, University of Minnesota, Minneapolis, MN
Background/Purpose: A patient registry is an organized system that collects uniform data to allow evaluation of specific outcomes for a population with a particular disease.…
Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting
Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus
Jon M. Burnham¹, Babette S. Zemel¹, David C. Lee², Tony M. Keaveny³ and Mary Beth Leonard¹, ¹Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²O.N. Diagnostics, LLC, Berkeley, CA, ³Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA
Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility. Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
Abstract Number: 1243 • 2013 ACR/ARHP Annual Meeting
Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting
Amy H. Warriner¹, Ryan C. Outman², Allison Wyman³, Fred H. Hooven⁴, Jonathan D. Adachi⁵, Roland Chapurlat⁶, Juliet E. Compston⁷, Cyrus Cooper⁸, Jeffrey R. Curtis⁹, Adolfo Díez-Pérez¹⁰, Robert Lindsay¹¹, Lyn March¹², Jeri W. Nieves¹¹ and Kenneth G. Saag¹³, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Center for Outcomes Research, Center for Outcomes Research, UMass Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵McMaster University, Hamilton, ON, Canada, ⁶Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, ⁷University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ⁸MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, ¹¹Helen Hayes, West Haverstraw, NY, ¹²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ¹³Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medication adherence with prescription osteoporosis medications is poor, with approximately half remaining adherent in the first year of treatment. Moreover, approximately one-third who are…
Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting
Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score
Jennifer Watt¹, Andrew E. Thompson², Nicole G. H. Le Riche³ and Janet E. Pope⁴, ¹Medicine, University of Western Ontario, London, ON, Canada, ²Rheumatology, St. Josephs Health Ctr, London, ON, Canada, ³Department of Medicine, St. Joseph's Hospital, London, ON, Canada, ⁴Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…
Abstract Number: 982 • 2013 ACR/ARHP Annual Meeting
Preferred Strategies For Delivering Treatment Information To People With Rheumatoid Arthritis, Osteoarthritis and Osteoporosis
Maria A. Lopez-Olivo¹, Robert Volk², Maria Jibaja-Weiss³ and Maria E. Suarez-Almazor⁴, ¹General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Office of Outreach and Health Disparities, Baylor College of Medicine, Houston, TX, ⁴The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: To explore the perceptions of people with rheumatoid arthritis (RA), osteoarthritis (OA), and osteoporosis (OP) regarding their preferred delivery methods for obtaining treatment information…
Abstract Number: 2732 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Autophagy Prevents Ovariectomy Induced Bone Loss
Neng-Yu Lin¹, Joerg H. W. Distler¹, Alfiya Distler¹, Christian Beyer¹, Georg Schett² and Oliver Distler³, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Autophagy is an essential, homeostatic process by which cells digest unnecessary or damaged organelles. Atg7 is essentially required for formation of the autophagosome. The…
Abstract Number: 2664 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Osteoporosis Medication Starts In Patients Based On T-Score and FRAX® Absolute Fracture Risk Model In a Large Health Care System
Robert A. Overman^1,2 and Chad L. Deal³, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: The National Osteoporosis Foundation (NOF) 2008 guidelines recommend treatment for postmenopausal women (PMW) and men ≥ 50 if the T-score is ≤-2.5 at the…
Abstract Number: 2266 • 2013 ACR/ARHP Annual Meeting
Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study
Masahiro Tada¹, Tatsuya Koike², Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui³ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption and formation are respectively increased and inhibited in patients with…
Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting
Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Hiroto Yoshida¹, Miho Suzuki¹, Misato Hashizume¹, Keisuke Tanaka², Masashi Shiina², Isao Matsumoto³, Takayuki Sumida³ and Yoshihiro Matsumoto², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, ³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
Abstract Number: 1991 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength
Roland Chapurlat¹, K. Brixen², A.M. Cheung³, Sharmila Majumdar⁴, B. Dardzinski⁵, A. Cabal⁵, N. Verbruggen⁶, S. Ather⁵, Elizabeth Rosenberg⁵ and A. de Papp⁵, ¹Hôpital Edouard Herriot, Lyon, France, ²University of Southern Denmark, Odense, Denmark, ³University of Toronto, Ontario, Canada, ⁴University of California San Francisco, San Francisco, CA, ⁵Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ⁶MSD Belgium, Brussels, Belgium
Background/Purpose: The cathepsin K inhibitor odanacatib (ODN), a novel antiresorptive that preserves bone formation, is currently in phase 3 development for postmenopausal osteoporosis. In a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].